PMRA unveils new five-year strategic plan
PMRA has today launched its new five-year strategic plan at a colourful ceremony held at the Bingu International Convention Centre (BICC) in Lilongwe.
Chairperson of the Parliamentary Committee on Health Dr. Matthews Ngwale presided over the launch which was also attended by USAID Health Office Deputy Director Dr. Haldon Njikho, WHO Rep Dr. Neema Kimambo and key players in the pharmaceutical sector, among others.
Chairperson of PMRA Board of Directors, Mrs Frider Chimimba described the development of the 2023/24-2027/28 blue print as a milestone towards enhancing service delivery.
Said she, “The Strategic Plan is part of the major strides the Authority is undertaking in its quest to further enhance the medicine regulatory system in the country. It comes at a time when PMRA has undergone functional review aimed at establishing new organizational structure in line with the PMRA Act, 2019 and formal WHO global benchmarking whose outputs include an institutional development plan (IDP) and a roadmap towards achieving WHO Maturity Levels II & III of a functioning national regulatory authority,”
The U.S. Agency for International Development (USAID) through its Promoting the Quality of Medicines Plus (PQM+) program supported the development of the SP.
PMRA unveils new five-year strategic plan
PMRA has today launched its new five-year strategic plan at a colourful ceremony held at the Bingu International Convention Centre (BICC) in Lilongwe.
Chairperson of the Parliamentary Committee on Health Dr. Matthews Ngwale presided over the launch which was also attended by USAID Health Office Deputy Director Dr. Haldon Njikho, WHO Rep Dr. Neema Kimambo and key players in the pharmaceutical sector, among others.
Chairperson of PMRA Board of Directors, Mrs Frider Chimimba described the development of the 2023/24-2027/28 blue print as a milestone towards enhancing service delivery.
Said Chimimba: “The Strategic Plan is part of the major strides the Authority is undertaking in its quest to further enhance the medicine regulatory system in the country. It comes at a time when PMRA has undergone functional review aimed at establishing new organizational structure in line with the PMRA Act, 2019 and formal WHO global benchmarking whose outputs include an institutional development plan (IDP) and a roadmap towards achieving WHO Maturity Levels II & III of a functioning national regulatory authority.”
The U.S. Agency for International Development (USAID) through its Promoting the Quality of Medicines Plus (PQM+) program supported the development of the SP.